Riskpilot← Back to searchSign inGet full accessTeromab AB
ABActiveOrg 5569149114Herrestads Lanesund 130Activities of holding companies · NACE 6421Est. 20120 employees
Revenue 2024
SEK 0
EBITDA margin
—
+57% vs 2023
Equity ratio
85.8%
Financial strength
Net profit 2024
SEK 998K
+29189% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1K | +57% |
| Net profit | SEK 998K | +29189% |
| Total assets | SEK 1,3M | +157% |
| Equity | SEK 1,1M | +1213% |
| Employees | 0 | — |
Legal name
Teromab AB
Org number
5569149114
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
13 december 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är fastighetsförvaltning med inriktning på ekonomisk och teknisk förvaltning och därmed förenlig verksamhet.
Address
Herrestads Lanesund 130
Phone
+46706696800
Email
gunnar.larsson@astreab.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 152 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −29 | 114 | −10 | −3 | −1 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −29 | 114 | −10 | −3 | −1 |
| Net financials | −10 273 | −9 | — | −0 | −1 000 |
| Profit before tax | −4 551 | 79 | 45 | −3 | 998 |
| Tax | −0 | −17 | −10 | — | −0 |
| Net profit | −4 551 | 62 | 35 | −3 | 998 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 124 | 514 | 490 | 490 | 1 258 |
| Equity | −231 | 51 | 86 | 82 | 1 080 |
| Long-term debt | 67 | 0 | — | — | — |
| Short-term debt | 111 | 259 | 255 | 258 | 29 |
| Total debt | 178 | 259 | 255 | 258 | 29 |
EBITDA margin
-135100.0%
This company
15.8%
Market median
-855163% vs market
20202024
Equity ratio
85.8%
This company
38.2%
Market median
+125% vs market
20202024
Return on equity
92.4%
This company
18.4%
Market median
+402% vs market
20202024
Net profit margin
99774800.0%
This company
8.1%
Market median
+1231787554% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LM Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Teromab AB 
Astreab ABBoard members of Teromab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Mattias Celind | Chief Auditor | 0 companies |
| Paul Erik Gunnar Larsson | Board of Directors | 0 companies |
| Lena Margareta Larsson | Deputy Board Member | 0 companies |